Atossa Therapeutics, Inc.
General ticker "ATOS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $84.9M (TTM average)
Atossa Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -24.7%.
Estimated limits based on current volatility of 3.5%: low 2.16$, high 2.31$
Factors to consider:
- Earnings expected soon, date: 2026-08-11 bmo
- Total employees count: 12 (+9.1%) as of 2023
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Operating losses, Capital raising, Clinical trial failure, Regulatory and compliance, Commercialization challenges
- Current price 65.3% below estimated low
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [5.97$, 15.24$]
- 2026-12-31 to 2027-12-31 estimated range: [5.61$, 14.37$]
Financial Metrics affecting the ATOS estimates:
- Negative: with PPE of -4.2 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -34.94 <= 0.30
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of -0.03 > -0.65
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: negative Industry operating cash flow (median)
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term ATOS quotes
Long-term ATOS plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $31.38MM | $27.62MM | $37.14MM |
| Operating Income | $-31.38MM | $-27.62MM | $-37.14MM |
| Non-Operating Income | $1.28MM | $2.12MM | $2.37MM |
| R&D Expense | $17.33MM | $14.12MM | $21.18MM |
| Income(Loss) | $-30.09MM | $-25.50MM | $-34.77MM |
| Net Income(Loss)* | $-30.09MM | $-25.50MM | $-34.77MM |
| Stockholders Equity | $91.02MM | $71.48MM | $39.35MM |
| Inventory | $1.49MM | $0.00MM | $0.00MM |
| Assets | $96.25MM | $76.44MM | $47.61MM |
| Operating Cash Flow | $-20.94MM | $-21.03MM | $-29.76MM |
| Capital expenditure | $0.01MM | $0.02MM | $0.02MM |
| Investing Cash Flow | $-0.01MM | $-0.02MM | $-0.02MM |
| Financing Cash Flow | $-1.48MM | $3.67MM | $0.00MM |
| Earnings Per Share** | $-3.58 | $-3.04 | $-4.04 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.